Jinyu Bio-technology Co., Ltd. Logo

Jinyu Bio-technology Co., Ltd.

600201.SS

(2.0)
Stock Price

6,47 CNY

4.39% ROA

5.05% ROE

29.02x PER

Market Cap.

8.221.594.128,00 CNY

0.07% DER

1.07% Yield

17.84% NPM

Jinyu Bio-technology Co., Ltd. Stock Analysis

Jinyu Bio-technology Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Jinyu Bio-technology Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

3 ROE

ROE in an average range (5.48%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (4.65%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 PBV

The stock's PBV ratio (2.04x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

The company's stock seems undervalued (48) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Jinyu Bio-technology Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Jinyu Bio-technology Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Jinyu Bio-technology Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Jinyu Bio-technology Co., Ltd. Revenue
Year Revenue Growth
1995 96.460.208
1996 97.634.241 1.2%
1997 151.323.181 35.48%
1998 155.127.144 2.45%
1999 165.621.503 6.34%
2000 196.735.283 15.82%
2001 208.264.083 5.54%
2002 293.236.335 28.98%
2003 334.033.382 12.21%
2004 466.899.407 28.46%
2005 552.597.984 15.51%
2006 561.866.923 1.65%
2007 702.180.147 19.98%
2008 815.014.679 13.84%
2009 685.494.694 -18.89%
2010 670.330.720 -2.26%
2011 576.140.310 -16.35%
2012 556.475.105 -3.53%
2013 671.382.978 17.12%
2014 1.062.932.025 36.84%
2015 1.246.505.844 14.73%
2016 1.517.019.283 17.83%
2017 1.901.010.264 20.2%
2018 1.896.608.630 -0.23%
2019 1.126.782.253 -68.32%
2020 1.581.905.632 28.77%
2021 1.776.317.811 10.94%
2022 1.528.669.256 -16.2%
2023 2.137.096.796 28.47%
2023 1.598.225.460 -33.72%
2024 1.055.319.224 -51.44%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Jinyu Bio-technology Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 11.341.311 100%
2011 23.176.313 51.07%
2012 17.336.697 -33.68%
2013 26.356.105 34.22%
2014 27.946.823 5.69%
2015 51.849.646 46.1%
2016 61.768.525 16.06%
2017 71.648.985 13.79%
2018 107.431.887 33.31%
2019 86.661.495 -23.97%
2020 130.828.817 33.76%
2021 165.939.974 21.16%
2022 133.778.931 -24.04%
2023 178.806.853 25.18%
2023 143.471.246 -24.63%
2024 107.843.800 -33.04%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Jinyu Bio-technology Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 2.790.990
1996 4.000.171 30.23%
1997 5.696.638 29.78%
1998 7.186.626 20.73%
1999 12.465.962 42.35%
2000 15.838.531 21.29%
2001 36.682.794 56.82%
2002 44.052.405 16.73%
2003 47.797.482 7.84%
2004 66.821.440 28.47%
2005 106.792.735 37.43%
2006 103.644.297 -3.04%
2007 66.653.230 -55.5%
2008 106.633.320 37.49%
2009 85.700.356 -24.43%
2010 24.592.632 -248.48%
2011 18.066.697 -36.12%
2012 20.314.241 11.06%
2013 23.702.944 14.3%
2014 31.634.721 25.07%
2015 36.756.503 13.93%
2016 42.951.963 14.42%
2017 37.205.584 -15.44%
2018 33.224.514 -11.98%
2019 32.231.641 -3.08%
2020 37.558.017 14.18%
2021 42.563.398 11.76%
2022 45.500.737 6.46%
2023 313.229.859 85.47%
2023 40.108.816 -680.95%
2024 -44.790.844 189.55%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Jinyu Bio-technology Co., Ltd. EBITDA
Year EBITDA Growth
1995 10.653.745
1996 10.508.531 -1.38%
1997 20.684.454 49.2%
1998 19.060.491 -8.52%
1999 16.809.463 -13.39%
2000 41.166.743 59.17%
2001 27.560.512 -49.37%
2002 60.954.266 54.78%
2003 59.525.769 -2.4%
2004 67.639.072 11.99%
2005 57.738.900 -17.15%
2006 86.789.524 33.47%
2007 228.109.601 61.95%
2008 192.848.372 -18.28%
2009 162.233.300 -18.87%
2010 184.050.676 11.85%
2011 236.113.521 22.05%
2012 220.342.429 -7.16%
2013 371.318.027 40.66%
2014 545.872.820 31.98%
2015 686.187.066 20.45%
2016 838.269.762 18.14%
2017 1.115.864.218 24.88%
2018 1.049.300.270 -6.34%
2019 406.308.336 -158.25%
2020 656.584.705 38.12%
2021 663.430.910 1.03%
2022 533.844.884 -24.27%
2023 743.280.378 28.18%
2023 569.047.950 -30.62%
2024 112.522.108 -405.72%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Jinyu Bio-technology Co., Ltd. Gross Profit
Year Gross Profit Growth
1995 15.195.264
1996 16.653.731 8.76%
1997 30.002.488 44.49%
1998 25.666.419 -16.89%
1999 28.700.868 10.57%
2000 33.332.208 13.89%
2001 73.912.797 54.9%
2002 116.661.836 36.64%
2003 131.302.850 11.15%
2004 175.789.731 25.31%
2005 236.279.463 25.6%
2006 235.917.523 -0.15%
2007 320.696.755 26.44%
2008 325.372.220 1.44%
2009 286.620.124 -13.52%
2010 318.719.721 10.07%
2011 395.461.067 19.41%
2012 374.870.376 -5.49%
2013 474.240.632 20.95%
2014 810.092.937 41.46%
2015 960.178.134 15.63%
2016 1.180.050.920 18.63%
2017 1.508.891.168 21.79%
2018 1.375.063.125 -9.73%
2019 702.154.372 -95.83%
2020 974.410.382 27.94%
2021 1.099.190.902 11.35%
2022 843.394.064 -30.33%
2023 1.351.537.821 37.6%
2023 945.979.057 -42.87%
2024 571.261.604 -65.59%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Jinyu Bio-technology Co., Ltd. Net Profit
Year Net Profit Growth
1995 19.623.484
1996 21.665.489 9.43%
1997 24.845.194 12.8%
1998 22.891.627 -8.53%
1999 30.493.628 24.93%
2000 25.901.190 -17.73%
2001 14.231.998 -81.99%
2002 40.165.309 64.57%
2003 44.154.107 9.03%
2004 44.199.860 0.1%
2005 12.281.769 -259.88%
2006 37.458.187 67.21%
2007 92.925.471 59.69%
2008 72.207.199 -28.69%
2009 66.473.720 -8.63%
2010 115.188.976 42.29%
2011 149.438.394 22.92%
2012 130.434.791 -14.57%
2013 250.883.061 48.01%
2014 404.321.363 37.95%
2015 479.727.738 15.72%
2016 644.541.675 25.57%
2017 870.094.412 25.92%
2018 754.465.552 -15.33%
2019 221.041.634 -241.32%
2020 406.195.463 45.58%
2021 382.286.663 -6.25%
2022 210.659.922 -81.47%
2023 615.537.323 65.78%
2023 283.630.790 -117.02%
2024 69.327.232 -309.12%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Jinyu Bio-technology Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 1 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Jinyu Bio-technology Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -43.688.595
1999 -114.338.130 61.79%
2000 33.265.451 443.71%
2001 -67.005.525 149.65%
2002 58.380.943 214.77%
2003 -104.223.488 156.02%
2004 13.068.879 897.49%
2005 -9.519.462 237.29%
2006 84.086.384 111.32%
2007 120.060.911 29.96%
2008 211.609.706 43.26%
2009 -71.243.053 397.03%
2010 -139.555.383 48.95%
2011 145.143.226 196.15%
2012 -17.086.284 949.47%
2013 534.270.842 103.2%
2014 378.555.815 -41.13%
2015 232.029.888 -63.15%
2016 621.873.536 62.69%
2017 489.487.272 -27.05%
2018 -123.006.187 497.94%
2019 97.882.972 225.67%
2020 471.297.209 79.23%
2021 160.401.064 -193.82%
2022 154.542.815 -3.79%
2023 70.094.537 -120.48%
2023 141.668.245 50.52%
2024 101.829.775 -39.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Jinyu Bio-technology Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -35.742.909
1999 -30.582.399 -16.87%
2000 97.799.408 131.27%
2001 -34.545.811 383.1%
2002 95.343.971 136.23%
2003 -51.040.056 286.8%
2004 81.061.665 162.96%
2005 28.290.477 -186.53%
2006 102.662.785 72.44%
2007 136.094.806 24.57%
2008 223.910.898 39.22%
2009 -24.497.004 1014.03%
2010 -95.751.725 74.42%
2011 185.203.233 151.7%
2012 102.946.417 -79.9%
2013 649.339.640 84.15%
2014 585.186.590 -10.96%
2015 494.320.157 -18.38%
2016 756.123.716 34.62%
2017 891.439.596 15.18%
2018 422.460.842 -111.01%
2019 405.242.914 -4.25%
2020 699.612.782 42.08%
2021 533.084.549 -31.24%
2022 344.650.092 -54.67%
2023 154.807.478 -122.63%
2023 414.833.263 62.68%
2024 112.749.631 -267.92%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Jinyu Bio-technology Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 7.945.687
1999 83.755.731 90.51%
2000 64.533.957 -29.79%
2001 32.459.714 -98.81%
2002 36.963.028 12.18%
2003 53.183.432 30.5%
2004 67.992.786 21.78%
2005 37.809.939 -79.83%
2006 18.576.401 -103.54%
2007 16.033.895 -15.86%
2008 12.301.191 -30.34%
2009 46.746.049 73.69%
2010 43.803.658 -6.72%
2011 40.060.007 -9.35%
2012 120.032.701 66.63%
2013 115.068.798 -4.31%
2014 206.630.775 44.31%
2015 262.290.269 21.22%
2016 134.250.180 -95.37%
2017 401.952.323 66.6%
2018 545.467.029 26.31%
2019 307.359.942 -77.47%
2020 228.315.572 -34.62%
2021 372.683.484 38.74%
2022 190.107.276 -96.04%
2023 84.712.941 -124.41%
2023 273.165.017 68.99%
2024 10.919.856 -2401.54%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Jinyu Bio-technology Co., Ltd. Equity
Year Equity Growth
1995 78.847.501
1996 79.432.140 0.74%
1997 83.196.484 4.52%
1998 333.060.401 75.02%
1999 334.576.212 0.45%
2000 344.795.904 2.96%
2001 517.192.939 33.33%
2002 529.815.685 2.38%
2003 573.941.410 7.69%
2004 609.023.025 5.76%
2005 577.159.722 -5.52%
2006 605.797.432 4.73%
2007 708.542.831 14.5%
2008 723.470.655 2.06%
2009 750.980.755 3.66%
2010 844.148.229 11.04%
2011 991.130.190 14.83%
2012 1.077.607.626 8.02%
2013 1.281.836.064 15.93%
2014 1.630.493.926 21.38%
2015 2.068.595.781 21.18%
2016 3.752.663.357 44.88%
2017 4.477.936.643 16.2%
2018 5.222.566.223 14.26%
2019 4.869.095.918 -7.26%
2020 5.262.939.862 7.48%
2021 5.560.232.913 5.35%
2022 5.349.655.458 -3.94%
2023 5.616.261.224 4.75%
2023 5.654.939.619 0.68%
2024 5.510.794.409 -2.62%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Jinyu Bio-technology Co., Ltd. Assets
Year Assets Growth
1995 213.086.275
1996 209.619.158 -1.65%
1997 203.867.311 -2.82%
1998 439.122.473 53.57%
1999 476.730.348 7.89%
2000 571.090.678 16.52%
2001 761.726.368 25.03%
2002 813.215.044 6.33%
2003 958.427.832 15.15%
2004 1.053.956.068 9.06%
2005 1.044.183.628 -0.94%
2006 940.076.097 -11.07%
2007 1.295.206.864 27.42%
2008 1.242.516.567 -4.24%
2009 1.399.132.631 11.19%
2010 1.588.783.696 11.94%
2011 1.725.322.563 7.91%
2012 1.882.838.912 8.37%
2013 1.711.664.428 -10%
2014 2.097.994.791 18.41%
2015 2.550.219.918 17.73%
2016 4.347.706.430 41.34%
2017 5.683.574.192 23.5%
2018 6.313.213.299 9.97%
2019 5.585.879.172 -13.02%
2020 6.278.282.683 11.03%
2021 6.603.925.651 4.93%
2022 6.389.335.025 -3.36%
2023 6.799.784.588 6.04%
2023 6.872.581.837 1.06%
2024 6.931.063.807 0.84%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Jinyu Bio-technology Co., Ltd. Liabilities
Year Liabilities Growth
1995 134.238.773
1996 130.187.017 -3.11%
1997 120.670.826 -7.89%
1998 106.062.071 -13.77%
1999 142.154.134 25.39%
2000 226.294.772 37.18%
2001 244.533.428 7.46%
2002 283.399.358 13.71%
2003 384.486.420 26.29%
2004 444.933.042 13.59%
2005 467.023.905 4.73%
2006 334.278.663 -39.71%
2007 586.664.032 43.02%
2008 519.045.911 -13.03%
2009 648.151.876 19.92%
2010 744.635.466 12.96%
2011 734.192.371 -1.42%
2012 805.231.285 8.82%
2013 429.828.363 -87.34%
2014 467.500.864 8.06%
2015 481.624.136 2.93%
2016 595.043.072 19.06%
2017 1.205.637.547 50.64%
2018 1.090.647.075 -10.54%
2019 716.783.253 -52.16%
2020 1.015.342.820 29.4%
2021 1.043.692.738 2.72%
2022 1.039.679.567 -0.39%
2023 1.183.523.363 12.15%
2023 1.217.642.217 2.8%
2024 1.420.269.397 14.27%

Jinyu Bio-technology Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.44
Net Income per Share
0.26
Price to Earning Ratio
29.02x
Price To Sales Ratio
5.39x
POCF Ratio
17.68
PFCF Ratio
41.3
Price to Book Ratio
1.47
EV to Sales
4.54
EV Over EBITDA
18.9
EV to Operating CashFlow
15.49
EV to FreeCashFlow
34.76
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
8,22 Bil.
Enterprise Value
6,92 Bil.
Graham Number
5.44
Graham NetNet
0.63

Income Statement Metrics

Net Income per Share
0.26
Income Quality
1.64
ROE
0.05
Return On Assets
0.04
Return On Capital Employed
0.05
Net Income per EBT
0.88
EBT Per Ebit
1
Ebit per Revenue
0.2
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.59
Operating Profit Margin
0.2
Pretax Profit Margin
0.2
Net Profit Margin
0.18

Dividends

Dividend Yield
0.01
Dividend Yield %
1.07
Payout Ratio
0.25
Dividend Per Share
0.08

Operating Metrics

Operating Cashflow per Share
0.42
Free CashFlow per Share
0.19
Capex to Operating CashFlow
0.55
Capex to Revenue
0.16
Capex to Depreciation
5.13
Return on Invested Capital
0.05
Return on Tangible Assets
0.04
Days Sales Outstanding
188.84
Days Payables Outstanding
148.98
Days of Inventory on Hand
182.37
Receivables Turnover
1.93
Payables Turnover
2.45
Inventory Turnover
2
Capex per Share
0.23

Balance Sheet

Cash per Share
1,27
Book Value per Share
5,22
Tangible Book Value per Share
4.52
Shareholders Equity per Share
5.1
Interest Debt per Share
0.01
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-3.56
Current Ratio
3.2
Tangible Asset Value
4,78 Bil.
Net Current Asset Value
1,04 Bil.
Invested Capital
4290598516
Working Capital
1,69 Bil.
Intangibles to Total Assets
0.11
Average Receivables
0,81 Bil.
Average Payables
0,28 Bil.
Average Inventory
305260696
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Jinyu Bio-technology Co., Ltd. Dividends
Year Dividends Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2005 0 0%
2006 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Jinyu Bio-technology Co., Ltd. Profile

About Jinyu Bio-technology Co., Ltd.

Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sales of veterinary biological products in China. It offers vaccines for foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever for pigs, poultry, ruminants, and pets. The company was formerly known as Inner Mongolia Jinyu Group Co., Ltd. and changed its name to Jinyu Bio-technology Co., Ltd. in December 2015. Jinyu Bio-technology Co., Ltd. was founded in 1992 and is based in Hohhot, China.

CEO
Ms. Jing Zhang
Employee
1.654
Address
No. 1, Jinyu Street
Hohhot, 010030

Jinyu Bio-technology Co., Ltd. Executives & BODs

Jinyu Bio-technology Co., Ltd. Executives & BODs
# Name Age
1 Mr. Min Peng
Chief Financial Officer, Secretary of the Board of Directors & Director
70
2 Mr. Rong Li
Vice President
70
3 Ms. Jing Zhang
Vice Chairman & President
70

Jinyu Bio-technology Co., Ltd. Competitors